AEB-071 has minimal impact on onset of autoimmune diabetes in NOD mice

References

• Aly T, Devendra D, Eisenbarth GS. Immunotherapeutic approaches to prevent, ameliorate, and cure type 1 diabetes. Am J Ther 2005; 12(6)481–490
   PubMedGoogle Scholar
• Evenou J-P, Brinkmann V, Towbin H, Welzenbach K, Cottens S, Wagner J, Morris R, Zenke G. Enzymatic cellular characterization of NVP-AEB071 (AEB), a novel selective protein kinase C (PKC) inhibitor that blocks early T cell activation, and its use to define the role of PKC in T cells. Am J Transplant 2006; 6(Supplement)4–1145
   Google Scholar
• Evenou J-P, Thuille N, Cottens S, Kovarik J, Wagner K, Zenke G, Baier G. NVP-AEB071 (AEB) a novel protein kinase C inhibitor, abrogates early mouse T cell activation without affecting activation induced cell death. Am J Transplant 2006; 6(Supplement)4–1145
   Google Scholar
• Hayashi K, Altman A. Protein kinase C theta (PKC theta): a key player in T cell life and death. Pharmacol Res 2007; 55(6)537–544
   PubMedGoogle Scholar
• Sun Z, Arendt CW, Ellmeier W, Schaeffer EM, Sunshine MJ, Gandhi L, Annes J, Petrzilka D, Kupfer A, Schwartzberg PL, et al. PKC-theta is required for TCR-induced NF-kappaB activation in mature but not immature T lymphocytes. Nature 2000; 404(6776)402–407
   PubMedGoogle Scholar
• Werlen G, Jacinto E, Xia Y, Karin M. Calcineurin preferentially synergizes with PKC-theta to activate JNK and IL-2 promoter in T lymphocytes. EMBO J 1998; 17(11)3101–3111
   PubMed Web of Science ®Google Scholar
• Ghaffari-Tabrizi N, Bauer B, Villunger A, Baier-Bitterlich G, Altman A, Utermann G, Uberall F, Baier G. Protein kinase C theta, a selective upstream regulator of JNK/SAPK and IL-2 promoter activation in Jurkat T cells. Eur J Immunol 1999; 29(1)132–142
   PubMedGoogle Scholar
• Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL, Kneteman NM, Rajotte RV. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 343(4)230–238
   PubMed Web of Science ®Google Scholar
• Shapiro AM, Ricordi C, Hering BJ, Auchincloss H, Lindblad R, Robertson RP, Secchi A, Brendel MD, Berney T, Brennan DC, et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med 2006; 355(13)1318–1330
   PubMed Web of Science ®Google Scholar
• Ryan EA, Paty BW, Senior PA, Bigam D, Alfadhli E, Kneteman NM, Lakey JR, Shapiro AM. Five-year follow-up after clinical islet transplantation. Diabetes 2005; 54(7)2060–2069
   PubMed Web of Science ®Google Scholar
• Merani S, Paullich R, Edgar R, Toso C, Emamaullee J, Anderson C, Shapiro AMJ. Protein Kinase C inhibitor, AEB–071, acts complementary with cyclosporine to prevent islet rejection in rats. Transplantation 2009, In Press
   PubMedGoogle Scholar
• Zeller W, Weber H, Panoussis B, Burge T, Bergmann R. Refinement of blood sampling from the sublingual vein of rats. Lab Anim 1998; 32(4)369–376
   PubMed Web of Science ®Google Scholar
• Yoon JW, Yoon CS, Lim HW, Huang QQ, Kang Y, Pyun KH, Hirasawa K, Sherwin RS, Jun HS. Control of autoimmune diabetes in NOD mice by GAD expression or suppression in beta cells. Science 1999; 284(5417)1183–1187
   PubMed Web of Science ®Google Scholar
• Truong W, Emamaullee JA, Merani S, Anderson CC, James Shapiro AM. Human islet function is not impaired by the sphingosine-1-phosphate receptor modulator FTY720. Am J Transplant 2007; 7(8)2031–2038
   PubMedGoogle Scholar
• Ma S, Huang Y, Yin Z, Menassa R, Brandle JE, Jevnikar AM. Induction of oral tolerance to prevent diabetes with transgenic plants requires glutamic acid decarboxylase (GAD) and IL-4. Proc Natl Acad Sci U S A 2004; 101(15)5680–5685
   PubMed Web of Science ®Google Scholar
• Tisch R, Liblau RS, Yang XD, Liblau P, McDevitt HO. Induction of GAD65-specific regulatory T-cells inhibits ongoing autoimmune diabetes in nonobese diabetic mice. Diabetes 1998; 47(6)894–899
   PubMedGoogle Scholar
• Pieper GM, Henderson JD, Jr, Roza AM, Lai CS. A dithiocarbamate analogue decreases intraislet cell infiltration and the incidence of diabetes mellitus in the genetic diabetes-prone BB rat. Pancreas 2004; 28(1)e16–e25
   Google Scholar
• Thliveris JA, Begleiter A, Manchur D, Johnston JB. Immunotherapy for insulin-dependent diabetes mellitus in the “BB” rat. Life Sci 1997; 61(3)283–291
   PubMedGoogle Scholar
• Baier G. PKC isotype functions in T lymphocytes. Ernst Schering Found Symp Proc 2007, 3: 29–41
   PubMedGoogle Scholar
• Bruns C, Pally C, Beerli C, Wieczorek G, Weckbecker G, Wagner J, Morris R. NVP-AEB071 (AEB) a novel oral inhibitor of early t-cell activation, prolons rat ardiac allograft surivval when used alone and in combination with cyclosporine, everolimus or FTY720. Am J Transplant 2006; 16(Supplement)316
   Google Scholar
• Bigaud M, Wieczorek G, Riesen S, Menninger K, Barbet I, Jean C, Beerli C, Audet M, Blancher A, Heusser C, et al. NVP-AEB071 (AEB), a novel oral inhibitor of early T cell activation, prolongs the survival of non-human primate kidney allografts when used as monotherapy or at non-effective doses combined with a non-effective dose of cyclosporine. Am J Transplant 2006; 6(Supplement)4–1145
   Google Scholar
• Mori Y, Suko M, Okudaira H, Matsuba I, Tsuruoka A, Sasaki A, Yokoyama H, Tanase T, Shida T, Nishimura M, et al. Preventive effects of cyclosporin on diabetes in NOD mice. Diabetologia 1986; 29(4)244–247
   PubMedGoogle Scholar
• Noorchashm H, Greeley SA, Naji A. The role of t/b lymphocyte collaboration in the regulation of autoimmune and alloimmune responses. Immunol Res 2003; 27(2–3)443–450
   PubMedGoogle Scholar
• Roep BO. Are insights gained from NOD mice sufficient to guide clinical translation? Another inconvenient truth. Ann N Y Acad Sci 2007; 1103: 1–10
   PubMedGoogle Scholar